Any current/future new fundraising through debt or equity?

The company had incurred a capital expenditure of Rs. 572 Cr in FY24 and plans to spend about Rs. 600-700 Cr in FY25 as part of the ongoing Rs. 2,000 Cr capex plan. Despite high capex, the company limited borrowings and actually decreased net debt by Rs. 48 Cr during the second half of FY24 via working capital optimization. Net debt as of March 31, 2024, stood at Rs. 653 Cr with a net debt to EBITDA ratio of 1.43 times. There is no explicit mention of any immediate or planned new fundraising through debt or equity in the transcript. The company may increase capex slightly beyond planned Rs. 60

Any current/future capex/capital investment/strategic investment?

Rs. 2,000 Crores capex plan announced over FY '22 to FY '25, with Rs. 1,400 Cr already committed and remaining Rs. 600-700 Cr to be spent mainly in FY '25. FY '25 capex includes investments in Food and Cosmetic Grade Niacinamide plant, new food grade choline (CC/CBT) plant, and expansion of GMP facilities for CDMO business. Future capex beyond FY '25 expected around Rs. 400-500 Cr per annum focusing on areas aligned with strategic priorities: Agrochemical expansions, diketene derivatives (Phase 3 and 4), microbial segment plants, and human nutrition premixes. New multipurpose Agro Active & Int

Future growth expectations in sales/revenue/volumes?

Specialty Chemical business expected to grow 3 to 3.5 times over next 3 years, constituting at least 60% of overall business. Growth to be driven by CDMO, fine chemical business (pyridine and diketene derivatives), and Microbial Solutions. CDMO segment seeing increasing inquiries, including semiconductors, with potential for rapid volume growth once product approvals occur. Nutrition business volumes are steady and growing; vitamin B3 global market share increased in FY24 despite pricing pressures. Company targets revenue potential of around Rs. 8,000 crores post ongoing capex investments. Con

Future growth expectations in earnings/operating earnings/profits/EPS?

Jubilant Ingrevia targets a bold 5-year growth strategy called Pinnacle 345 aiming for 3x revenue and 4x EBITDA growth. Steady-state overall EBITDA margins are expected to exceed 20%, with specialty chemicals margin higher than this benchmark. Specialty chemical business margins are projected at 17-18% currently, improving to above 20% in 3-4 years as the specialty mix grows from ~40-50% to 60-70%. The company expects a steady-state EBITDA margin north of 20% driven by specialty chemicals and nutrition segments with optimized operations. Net profit (PAT) took a hit in FY24 (Rs. 183 Cr

Current/ Expected Orderbook/ Pending Orders?

Jubilant Ingrevia has a full potential roadmap/visibility to at least Rs. 8,000 crores in orderbook or pending orders. This outlook is based on the capex and growth plans they have executed and those planned in the current fiscal year. The company has committed Rs. 1,400 crores of a Rs. 2,000 crore capex over the past 2-3 years, with remaining Rs.600 crores planned for this fiscal. Some opportunities are identified but pending formal capex approval (e.g., CC/CBT specialty nutrition and GMP-3 for CDMO business). Large customer contracts and long-term arrangements may increase this capex

IN US

Sale is live|00:00:00left today

Jubilant Ingrevia LtdQ1 FY24Chemicals & Petrochemicals

Jubilant Ingrevia Ltd Q1 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹632P/E: 42.4Market Cap: ₹11.7K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 2

Margin

Category 1

Fundraise

Yes

Order

Yes

Capex

Yes

4 of 5 growth signals are positive — a strong management growth story.

Full analysis

Revenue guidance

Category 2

→Specialty Chemical business expected to grow 3 to 3.5 times over next 3 years, constituting at least 60% of overall business.
→Growth to be driven by CDMO, fine chemical business (pyridine and diketene derivatives), and Microbial Solutions.
→CDMO segment seeing increasing inquiries, including semiconductors, with potential for rapid volume growth once product approvals occur.
→Nutrition business volumes are steady and growing; vitamin B3 global market share increased in FY24 despite pricing pressures.
→Company targets revenue potential of around Rs. 8,000 crores post ongoing capex investments.
→Continued focus on customer-centricity and ramping up newly commissioned plants.
→Anticipated top-line growth aligned with “Pinnacle 345” strategy aiming for 3x revenue and 4x EBITDA in 5 years.
→Capex plans beyond FY25 indicate further expansion with Rs. 400-500 crores per annum to support 3x revenue growth from current baseline.

Margin guidance

Category 1

→Jubilant Ingrevia targets a bold 5-year growth strategy called Pinnacle 345 aiming for 3x revenue and 4x EBITDA growth.
→Steady-state overall EBITDA margins are expected to exceed 20%, with specialty chemicals margin higher than this benchmark.
→Specialty chemical business margins are projected at 17-18% currently, improving to above 20% in 3-4 years as the specialty mix grows from ~40-50% to 60-70%.
→The company expects a steady-state EBITDA margin north of 20% driven by specialty chemicals and nutrition segments with optimized operations.
→Net profit (PAT) took a hit in FY24 (Rs. 183 Cr vs Rs. 308 Cr in FY23) due to pricing pressure but is expected to improve with margin expansion and volume growth.
→Capex plans of Rs. 2,000 Cr over FY22-25 plus additional Rs. 1,500-2,000 Cr beyond FY25 aim to drive revenue towards Rs. 8,000 Cr, supporting strong growth in earnings going forward.
→New high-potential specialty products including CDMO (contract development and manufacturing) and nutrition areas are key future profit drivers.

3 more insights locked — sign up free to unlock

Fundraise plans

Yes

→The company had incurred a capital expenditure of Rs. 572 Cr in FY24 and plans to spend about Rs. 600-700 Cr in FY25 as part of the ongoing Rs. 2,000 Cr capex plan.
→Despite high capex, the company limited borrowings and actually decreased net debt by Rs. 48 Cr during the second half of FY24 via working capital optimization.
→Net debt as of March 31, 2024, stood at Rs. 653 Cr with a net debt to EBITDA ratio of 1.43 times.
→There is no explicit mention of any immediate or planned new fundraising through debt or equity in the transcript.
→The company may increase capex slightly beyond planned Rs. 600 Cr if long-term contracts with customers are signed, but no direct reference to raising new funds was made.

Order book

Yes

→Jubilant Ingrevia has a full potential roadmap/visibility to at least Rs. 8,000 crores in orderbook or pending orders.
→This outlook is based on the capex and growth plans they have executed and those planned in the current fiscal year.
→The company has committed Rs. 1,400 crores of a Rs. 2,000 crore capex over the past 2-3 years, with remaining Rs.600 crores planned for this fiscal.
→Some opportunities are identified but pending formal capex approval (e.g., CC/CBT specialty nutrition and GMP-3 for CDMO business).
→Large customer contracts and long-term arrangements may increase this capex/order pipeline beyond Rs. 600 crores currently planned this year.
→The business mix and new plant commissioning, especially in specialty chemicals and nutrition segments, support strong order inflow visibility.

Capex plans

Yes

→Rs. 2,000 Crores capex plan announced over FY '22 to FY '25, with Rs. 1,400 Cr already committed and remaining Rs. 600-700 Cr to be spent mainly in FY '25.
→FY '25 capex includes investments in Food and Cosmetic Grade Niacinamide plant, new food grade choline (CC/CBT) plant, and expansion of GMP facilities for CDMO business.
→Future capex beyond FY '25 expected around Rs. 400-500 Cr per annum focusing on areas aligned with strategic priorities: Agrochemical expansions, diketene derivatives (Phase 3 and 4), microbial segment plants, and human nutrition premixes.
→New multipurpose Agro Active & Intermediate plant commissioned at Bharuch. New Diketene Derivatives plant commissioned at Gajraula.
→A GMP-compliant facility for Food & Cosmetic grade B3 is expected to be commissioned in Q3 FY '25.
→Additional capex may be required (Rs. 1,500-2,000 Cr) for achieving 3x revenue growth beyond the original plan.
→Capex investments are only approved with internal criteria of >20% EBITDA margin and >20% ROCE.

How does Jubilant Ingrevia Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

1Jubilant Ingrevia Ltd

Rev 2Mar 1

See full Chemicals & Petrochemicals sector rankings

Want more stocks like Jubilant Ingrevia Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio